Work

A Case of Anti‐TNFα Therapies Induced Lupus Panniculitis Successfully Improved With a JAK Inhibitor (Baricitinib)

Year: 2025

Type: article

Abstract: ABSTRACT Lupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus (1%–3% of CLE). There are two case reports to date in the literature of LEP potentially triggered by anti‐TNF‐α therapies. Clinically, it is characterised by tender, erythematous subcutaneous indurated nodules or plaques on fatty body areas. It can occur frequently alone or in combination with systemic erythematous lupus or discoid lupus. The pathogenic mechanism of anti‐TNF‐α therapies induced lupus panniculitis is not well understood. Our case report and literature review highlight that anti‐TNF‐α therapies can induce lupus panniculitis, especially in the rheumatoid arthritis cohort of patients.

Source: JEADV Clinical Practice

DOI: 10.1002/jvc2.626

Authors: Cristina Grechin, Jane Doheny, Keith Pilson, Donough Howard, Muireann Roche

Institution: Beaumont Hospital

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,310